AgenT

Executive Summary

AgenT is a French biotechnology company founded in 2018, headquartered in Paris, dedicated to transforming Alzheimer's disease diagnosis through a pioneering multiomics blood test. The company's platform integrates the analysis of proteins and metabolites in blood plasma with advanced machine learning algorithms to detect Alzheimer's disease up to 20 years before the onset of irreversible symptoms. By decoding the body's early molecular response, AgenT aims to enable earlier intervention and improve patient outcomes. As a privately held, early-stage diagnostics company, AgenT has not yet disclosed funding or valuation details, but its innovative approach addresses a critical unmet need in neurodegenerative disease management. The company's technology could significantly impact the Alzheimer's diagnostic landscape, potentially reducing reliance on costly and invasive traditional methods such as PET scans and lumbar punctures. With a strong focus on blood-based biomarkers and AI-driven analytics, AgenT is positioned to capitalize on the growing demand for accessible, scalable, and early diagnostic solutions.

Upcoming Catalysts (preview)

• Q4 2026Initial Clinical Validation Data Readout65% success
• Q1 2027Strategic Partnership with Diagnostics or Pharma Company60% success
• Q2 2027Series A or B Funding Round Announcement75% success